Unable to connect, retrying...
Online collaborative whiteboard. Powerful, engaging with timer, emoji's, commenting and voting.
Search for RSS feeds

Las empresas deberían innovar para incorporar la salud cer...sus actividades de formación y liderazgo, según una encuesta

Encuesta Internacional sobre Tendencias y Creencias sobre la Salud Cerebral entre Expertos y ‘early adopters’, elaborada por el think-tank SharpBrains Un 85% de los encuestados se mostraron a...

https://sharpbrains.com/blog/2024/04/30/las-empresas-deberian-innovar-para-incorporar-la-salud-cerebral-y-mental-en-sus-actividades-de-formacion-y-liderazgo-segun-una-encuesta/

Study: Cognitively stimulating jobs help us maintain brain ...e age, delaying the onset of cognitive impairment and dementia

Workplace learning could be a boon for wellness, research shows (HR DIVE): Learning and development in the workplace could be a boon for wellness, new research suggests. Doing cognitively demandi...

https://sharpbrains.com/blog/2024/04/26/study-cognitively-stimulating-jobs-help-maintain-brain-health-as-we-age-delaying-the-onset-of-cognitive-impairment-and-dementia/

Executive Functions and Dysfunction in Brain Health and Bra...nnounced for Dr. Elkhonon Goldberg’s Symposium in Costa Rica

We are pleased to announce a fantastic 5‑day professional development opportunity featuring our Advisor and renowned author and neuropsychologist Elkhonon Goldberg, Ph.D., ABPP., and titled “...

https://sharpbrains.com/blog/2024/03/07/executive-functions-and-dysfunction-in-brain-health-and-brain-disorders-dates-announced-for-dr-elkhonon-goldbergs-symposium-in-costa-rica/

Systematic review finds more clinical harm than benefits in...imer’s “treatments” lecanemab, aducanumab, and donanemab

Study questions benefit of new Alzheimer’s drug (UGA Today): Last summer, the U.S. Food and Drug Administration fully approved the first drug shown to slow the progress of Alzheimer’s. But ne...

https://sharpbrains.com/blog/2024/02/09/systematic-review-finds-more-clinical-harm-than-benefits-in-alzheimers-treatments-lecanemab-aducanumab-and-donanemab/